Phase II Study of Gemcitabine and Vinorelbine Combination Chemotherapy in Patients with Non-Small-Cell Lung Cancer Not Responding to Previous Chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 6, 2003, Pages 567-570

  Chen, Yuh Min ^a,c   Perng, Reury Perng ^a   Lee, Chia San ^a   Lin, Wei Chun ^b   Tsai, Chun Ming ^a   Whang Peng, Jacqueline ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Gemcitabine; Non small cell lung cancer; Salvage chemotherapy; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; GEMCITABINE; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0346850879     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000045808.39041.49     Document Type: Article

References (19)

1. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-62.
2. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
3. Pemg RP, Chen YM, Liu JM, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997;15:2097-102.
4. Van Kooten M, Traine G, Cinat G, et al. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial. Br J Cancer 1999;81:846-9.
5. Sculier JP, Lafitte JJ, Berghamans T, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. Lung Cancer 2000;29:67-73.
6. Van Putten JW, Baas P, Codrington H, et al. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer 2001;33:289-98.
7. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-30.
8. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
9. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell-lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-65.
10. Belani CP. Single agents in the second-line treatment of non-small-cell lung cancer. Semin Oncol 1998;25(suppl 8):10-4.
11. Gridelli C, Frontini L, Perrone F, et al. Gemcitabine plus vinorelbine in advanced non-small-cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br J Cancer 2000;83:707-14.
12. Bajetta E, Chiara Stani S, De Candis D, et al. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced non-small-cell lung carcinoma a phase II trial. Cancer 2000;89:763-8.
13. Chen YM, Perng RP, Yang KY, et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small-cell lung cancer. Chest 2000;117:1583-9.
14. Lilenbaum R, Cano R, Schwartz M, et al. Gemcitabine and vinorelbine in advanced non-small-cell lung carcinoma: a phase II study. Cancer 2000;88:557-62.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
16. Kosmas C, Tsavaris N, Panopoulos C, et al. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur J Cancer 2001;37:972-8.
17. Camps C, Martinez EN, Jaime AB. Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. Lung Cancer 2000;27:47-53.
18. Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small-cell lung carcinoma patients: a Minnie Pearl cancer research network phase II trial. Cancer 2000;88:1353-8.
19. Androulakis N, Kouroussis C, Kakolyris S, et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 1998;9:1127-30.